Other PSMA-directed radiotracers, including [68Ga]Ga-PSMA-617 (Figure 5b) and [68Ga]Ga-PSMA-I&T (Figure 5c), exhibit comparable pharmacokinetic and imaging characteristics, further validating the robustness of PSMA as a target for prostate cancer imaging [77]. This evidence concerns the gene FOLH1 and prostate cancer.